Drug Profile
Simtuzumab - Gilead Sciences
Alternative Names: AB-0024; Anti-LOXL2 monoclonal antibody; GS-6624Latest Information Update: 13 Jul 2023
Price :
$50
*
At a glance
- Originator Arresto Biosciences
- Developer Gilead Sciences
- Class Antifibrotics; Antineoplastics; Hepatoprotectants; Monoclonal antibodies
- Mechanism of Action Chemokine CXCL12 inhibitors; Connective tissue growth factor inhibitors; LOXL2 protein inhibitors; Transforming growth factor beta1 inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Colorectal cancer; Hepatic fibrosis; Idiopathic pulmonary fibrosis; Liver cirrhosis; Myelofibrosis; Non-alcoholic steatohepatitis; Pancreatic cancer; Primary sclerosing cholangitis
Most Recent Events
- 19 May 2023 Pharmacodynamics data from a phase II trial in Idiopathic pulmonary fibrosis presented at the 119th International Conference of the American Thoracic Society (ATS-2023)
- 11 Apr 2018 Pooled efficacy data from two phase IIb trials in indication) presented at the Nonalcoholic steatohepatitis and Cirrhosis presented at The International Liver Congress 2018 (ILC-2018)
- 20 Apr 2017 Interim efficacy data from a phase IIb trial in Non-alcoholic steatohepatitis released by Gilead Sciences